85 Percent of CyberKnife(R) Sites Within Europe Performing Prostate Stereotactic Body Radiation Therapy (SBRT)

By Accuray Incorporated, PRNE
Tuesday, May 10, 2011

This Recognition of Clinical Benefits Across Europe is Supported by Five-Year Outcomes for Low-Risk Prostate Cancer Patients Treated in Five Sessions

SUNNYVALE, California, May 11, 2011 - Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of
radiosurgery, announced today that 85 percent of European CyberKnife(R)
centers are performing prostate SBRT to treat localized prostate cancer.
There is an increasing trend towards treating prostate cancer patients with a
hypofractionated regimen.

"More than 25 percent of our CyberKnife patients are being treated for
prostate cancer with further growth anticipated," said Dr David Feltl, Head
of the Oncology department, Ostrava University Hospital, Ostrava, Czech

At the Annual Congress of the European Society for Therapeutic Radiology
and Oncology (ESTRO) in London, UK this growth was supported by strong
clinical evidence presented at a symposium focused on prostate cancer
co-chaired by Prof. Eric Lartigau, Centre Oscar Lambret, Lille, France, and
Prof. Volker Budach, M.D., Ph.D., Charite - Universitatsmedizin Berlin,

"Offering CyberKnife non-invasive treatments to our patients provides
excellent 5-year tumor control and very low level of toxicity as recently
published in Radiation Oncology 2011," said Prof. Eric Lartigau.

"There is a strong academic interest to further drive prospective
randomized clinical evidence for prostate SBRT with the CyberKnife System
leading the clinical trend," said Prof. Volker Budach.

"The long term efficacy and toxicity outcomes of single and multi-center
studies are supported by many key publications and presentations on
CyberKnife prostate SBRT. Supported by an increasing foundation of solid
clinical evidence we have seen a 20 percent increase in worldwide prostate
cancer treatment as compared to a similar period last year," said Omar
, vice president, Medical Affairs, Accuray Incorporated.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body
non-invasively. Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in real-time throughout
the treatment. This enables the CyberKnife System to deliver high-dose
radiation with pinpoint precision, which minimizes damage to surrounding
healthy tissue and eliminates the need for invasive head or body
stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a
global leader in the field of radiosurgery dedicated to providing an improved
quality of life and a non-surgical treatment option for those diagnosed with
cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery
System, which extends the benefits of radiosurgery to include extracranial
tumors, including those in the spine, lung, prostate, liver and pancreas. To
date, the CyberKnife System has been used to treat more than 100,000 patients
worldwide and currently more than 226 systems have been installed in leading
hospitals in the Americas, Europe and Asia. For more information, please
visit www.accuray.com.

Safe Harbor Statement

This press release contains forward-looking statements, including those
concerning Accuray's expectations about revenue for fiscal year 2011, the
portion of revenue attributable to CyberKnife System revenue, gross margin,
profitability, customer installation schedules, realization of backlog and
service activity. Forward looking statements involve risks and uncertainties
that may lead to actual results varying materially from the forward looking
statements. Accordingly, investors are cautioned not to place undue reliance
on such statements. Many factors could cause actual performance or results to
differ materially from these forward looking statements, including, but not
limited to the uncertainties associated with the medical device industry;
variability of installation and sales cycle including customer financing and
construction delays; changes in the regulatory environment, including
reimbursement for CyberKnife procedures; market acceptance of products; and
the impact of competition. These and other risks are discussed under the
heading "Risk Factors" in our report on Form 10-K for the 2010 fiscal year
which has been filed with the Securities and Exchange Commission, as updated
in our Form 10-Q to be filed on or before May 10, 2011. The Company assumes
no obligation to update forward-looking statements to reflect actual
performance or results, changes in assumptions or changes in other factors
affecting forward-looking information.

Sancie Nakarat, Manager, EU Marketing, + 33(0)6-81-36-84-34, snakarat at accuray.com, Charlotte Taccon, Edelman Paris, + 33 (0)1-56-69-75-19, charlotte.taccon at edelman.com

Clinical Trials / Medical Discoveries News

Accuray Incorporated News

will not be displayed